Opinion

Video

Shared Decision-Making in Tardive Dyskinesia

Author(s):

Jason Noel, PharmD, MPA, BCPP,Julie Dopheide, PharmD, BCPP, FASHP

Panelists discuss how TD treatment can be optimized through individualized approaches that consider patient-specific factors like symptom severity, comorbidities, concurrent medications, and daily routines, utilizing tools like titration kits to carefully adjust VMAT2 inhibitor dosing while monitoring response and tolerability to achieve the best possible outcomes for each patient.

Video series above is prompted by the following:

  • How can treatment strategies for TD be individualized (eg, titration kits) based on patient-specific factors?

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
1 expert in this video
1 expert in this video
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
1 expert in this video
1 expert in this video
Related Content
Neuron cells, brain activity -- Image credit: Matthieu | stock.adobe.com
March 4th 2024

Integration of DBS Shows Promise Identifying Dysfunctional Brain Circuits, Treating Brain Disorders

Gillian McGovern, Associate Editor
Elderly man putting together a puzzle -- Image credit: LIGHTFIELD STUDIOS | stock.adobe.com
February 5th 2024

Study Results Highlight Importance of Overcoming Stigma When Addressing Brain Health

Gillian McGovern, Associate Editor
3d illustration of human body organ -- Image credit: PIC4U | stock.adobe.com
January 22nd 2024

Study Findings Suggest Liver Creates Palmitic Acid, Maintaining Brain Health

Gillian McGovern, Associate Editor
Burgundy ribbon for multiple myeloma cancer awareness
January 15th 2024

Individuals With Obesity More Likely to Have MGUS, A Multiple Myeloma Precursor

Gillian McGovern, Associate Editor
FDA Accepts sBLA for Tisotumab Vedotin-tftv for the Treatment of Recurrent, Metastatic Cervical Cancer
January 9th 2024

FDA Accepts sBLA for Tisotumab Vedotin-tftv for the Treatment of Recurrent, Metastatic Cervical Cancer

Gillian McGovern, Associate Editor
Image credit: Dglimages | stock.adobe.com
January 9th 2024

Study Data Show Telemedicine Endocrinology Care Not as Effective as In-Person Care

Erin Hunter, Associate Editor